A Supreme Court case over whether to tighten restrictions on mifepristone – one of two drugs used in the medication abortion regimen – could destabilize the American pharmaceutical industry, deterring companies from developing new drugs and even inspiring copycat lawsuits intended to revoke authorization of other politically contentious medications.
Read more at 19th News